Cargando…
Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477632/ https://www.ncbi.nlm.nih.gov/pubmed/37675296 http://dx.doi.org/10.21037/atm-2023-5 |
| _version_ | 1785101174974709760 |
|---|---|
| author | Wongariyapak, Amarin Roulstone, Victoria Melcher, Alan A. Pedersen, Malin Harrington, Kevin J. |
| author_facet | Wongariyapak, Amarin Roulstone, Victoria Melcher, Alan A. Pedersen, Malin Harrington, Kevin J. |
| author_sort | Wongariyapak, Amarin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10477632 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104776322023-09-06 Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence? Wongariyapak, Amarin Roulstone, Victoria Melcher, Alan A. Pedersen, Malin Harrington, Kevin J. Ann Transl Med Editorial Commentary AME Publishing Company 2023-03-17 2023-08-30 /pmc/articles/PMC10477632/ /pubmed/37675296 http://dx.doi.org/10.21037/atm-2023-5 Text en 2023 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Wongariyapak, Amarin Roulstone, Victoria Melcher, Alan A. Pedersen, Malin Harrington, Kevin J. Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence? |
| title | Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence? |
| title_full | Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence? |
| title_fullStr | Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence? |
| title_full_unstemmed | Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence? |
| title_short | Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence? |
| title_sort | combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477632/ https://www.ncbi.nlm.nih.gov/pubmed/37675296 http://dx.doi.org/10.21037/atm-2023-5 |
| work_keys_str_mv | AT wongariyapakamarin combinationstrategiesincorporatingoncolyticvirusesandimmunecheckpointinhibitorsforadvancedmelanomawhatistheevidence AT roulstonevictoria combinationstrategiesincorporatingoncolyticvirusesandimmunecheckpointinhibitorsforadvancedmelanomawhatistheevidence AT melcheralana combinationstrategiesincorporatingoncolyticvirusesandimmunecheckpointinhibitorsforadvancedmelanomawhatistheevidence AT pedersenmalin combinationstrategiesincorporatingoncolyticvirusesandimmunecheckpointinhibitorsforadvancedmelanomawhatistheevidence AT harringtonkevinj combinationstrategiesincorporatingoncolyticvirusesandimmunecheckpointinhibitorsforadvancedmelanomawhatistheevidence |